All In Biotech

Drug Trial Radar · NCT05293964

Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

A Multicenter, Open-label, Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Efficacy of SIM0270 Alone or in Combination in Subjects with ER-positive, HER-2 Negative Locally Advanced or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

214

Actual

Start

May 18, 2022

Primary completion

Dec 31, 2024

Study completion Sep 8, 2025

Sponsor

Sponsor type
Industry
Collaborators
Nanjing Zaiming Pharmaceutical Co., Ltd.
First posted
Mar 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multi-center, open-label, Phase 1 clinical study to evaluate the safety, pharmacokinetic (PK) and anti-tumor efficacy of SIM0270 and SIM0270 in combination with palbociclib or everolimus in subjects with estrogen receptor (ER) -positive, human epidermal growth factor receptor (HER-2) -negative locally advanced or metastatic breast cancer.

Conditions

  • Breast Cancer

Interventions

  • SIM0270Drug

    SIM0270 is an oral, selective estrogen receptor degrader (SERD)

  • PalbociclibDrug

    palbociclib is a selective inhibitor of cyclin D-cyclin-dependent kinase (CDK) 4/6

  • everolimusDrug

    Everolimus is an inhibitor of mTOR (mammalian target of rapamycin)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated DoseTime frame: At the end of Cycle 1 (each cycle is 28 days)
  2. recommended phase 2 DoseTime frame: At the end of Cycle 1 (each cycle is 28 days)
  3. Dose-Limiting ToxicitiesTime frame: At the end of Cycle 1 (each cycle is 28 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.